Royalty Pharma's total assets for Q4 2024 were $18.22B, an increase of 1.00% from the previous quarter. RPRX total liabilities were $7.88B for the fiscal quarter, a 1.24% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.